Understanding Paratyphoid Infection

University of Oxford80 enrolled

Overview

Enteric fever is responsible for over 20 million illnesses and 200,000 deaths each year. S. Paratyphi A accounts for a substantial and increasing proportion of these cases, as high as 90% in some regions of Asia. There are currently no vaccines directed against S. Paratyphi A, although there some candidates in preclinical and phase 1 trials. This study is funded by the European Vaccine Initiative and the Bill and Melinda Gates Foundation. Paratyphoid is a human-restricted infection, for which there are currently no small animal models available. In order to further our understanding of the host-pathogen interactions, this study will develop a novel human challenge model in which to investigate this infection, using a recent successful typhoid challenge model as its template. Healthy subjects to ingest a dose of Salmonella enterica serovar Paratyphi A, strain NVGH308, after drinking a bicarbonate buffer. Intensive follow up over 14 days will establish whether each participant meets clearly defined criteria for diagnosis of paratyphoid infection. Statistical analysis will be performed on this outcome will determine if it consistently gives an attack rate of 60 to 75%. If this is not reached with the first cohort of 20 participants, the dose will be escalated and the process repeated. A maximum of 80 participants will be enrolled. Total follow up will be over the course of one year. Descriptive clinical and laboratory data collected from participant observations, samples of blood, faeces, urine and saliva will allow insights into the disease and the host response. These insights will forward our knowledge of paratyphoid disease and may help discover or develop diagnostic methods. This study is funded by the European Vaccine Initiative and the Bill and Melinda Gates Foundation. Paratyphoid is a human-restricted infection, for which there are currently no small animal models available. In order to further our understanding of the host-pathogen interactions, this study will develop a novel human challenge model in which to investigate this infection, using a recent successful typhoid challenge model as its template. Healthy subjects will ingest a dose of Salmonella enterica serovar Paratyphi A, strain NVGH308, after drinking a bicarbonate buffer. Intensive follow up over 14 days will establish whether each participant meets clearly defined criteria for diagnosis of paratyphoid infection. Statistical analysis will be performed on this outcome will determine if it consistently gives an attack rate of 60 to 75%. If this is not reached with the first cohort of 20 participants, the dose will be escalated and the process repeated. A maximum of 80 participants will be enrolled. Total follow up will be over the course of one year. Descriptive clinical and laboratory data collected from participant observations, samples of blood, faeces, urine and saliva will allow insights into the disease and the host response. These insights will forward our knowledge of paratyphoid disease and may help discover or develop diagnostic methods. Anticipating the development of a successful live challenge model through this study, there will be the possibility of evaluating novel paratyphoid vaccines that are currently in early clinical phase testing. This serves an important function because field trials in endemic areas are expensive and time consuming. Speeding up this process using our model will be of great benefit to endemic areas.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Agree to give informed consent for participation in the study. * Aged between 18 and 60 years inclusive at time of challenge. * In good health as determined by medical history, physical examination and clinical judgment of the investigators. * Agree (in the Investigator's opinion) to comply with all study requirements, including capacity to adhere to good personal hygiene and infection control precautions. * Agree to allow his or her General Practitioner (and/or Consultant if appropriate), to be notified of participation in the study. * Agree to allow Public Health England to be informed of their participation in the study. * Agree to give his or her close household contacts written information informing them of the participants' involvement in the study and offering them voluntary screening for S. Paratyphi carriage. * If diagnosed with paratyphoid infection: agree to refrain from future blood donation to the National Blood Service. * Agree to have 24-hour contact with study staff during the four weeks post challenge and are able to ensure that they are contactable by mobile phone for the duration of the challenge period until antibiotic completion. * Have internet access to allow completion of the eDiary and real-time safety monitoring. * Agree to avoid antipyretic/anti-inflammatory treatment until advised by a study doctor or until 14 days after challenge. * Agree to provide their National Insurance/Passport number for the purposes of TOPS registration and for payment of reimbursement expenses. Exclusion Criteria: * History of significant organ/system disease that could interfere with trial conduct or completion. Including, for example, but not restricted to: * Cardiovascular disease * Respiratory disease * Hematological disease * Endocrine disorders * Renal or bladder disease, including history of renal calculi * Biliary tract disease, including biliary colic, asymptomatic gallstones or previous cholecystectomy * Gastro-intestinal disease including requirement for antacids, H2-receptor antagonists, proton pump inhibitors or laxatives * Neurological disease * Metabolic disease * Autoimmune disease * Psychiatric illness requiring hospitalization or known or suspected drug and/or alcohol misuse (alcohol misuse defined as an intake exceeding 42 units per week) * Infectious disease. * Have any known or suspected impairment of immune function, alteration of immune function, or prior immune exposure that may alter immune function to paratyphoid resulting from, for example: * Congenital or acquired immunodeficiency, including IgA deficiency * Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition * Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy * Receipt of immunoglobulin or any blood product transfusion within 3 months of study start. * History of cancer (except squamous cell or basal cell carcinoma of the skin and cervical carcinoma in situ). * Moderate or severe depression or anxiety as classified by the Hospital Anxiety and Depression Score at screening or challenge that is deemed clinically significant by the study investigators. * Weight less than 50kg. * Presence of implants or prosthesis. * Anyone taking long-term medication (e.g. analgesia, anti-inflammatories or antibiotics) that may affect symptom reporting or interpretation of the study results. * Contra-indication to ciprofloxacin, beta-lactam antibiotics and trimethoprim/sulfamethoxazole therapy. * Female participants who are pregnant, lactating or who are unwilling to ensure that they or their partner use effective contraception one month prior to challenge and continue to do so until two negative stool samples, a minimum of 2 weeks after completion of antibiotic treatment, has been obtained. * Full-time, part-time or voluntary occupations involving: * Clinical or social work with direct contact with young children (defined as those attending pre-school groups or nursery or aged under 2 years), or * Clinical or social work with direct contact with highly susceptible patients or persons in whom paratyphoid infection would have particularly serious consequences (unless willing to avoid work until demonstrated not to be infected with S. Paratyphi in accordance with guidance from Public Health England and willing to allow us to inform their employer). * Full time, part time or voluntary occupations involving: o Commercial food handling (involving preparing or serving unwrapped foods not subjected to further heating) * Close household contact with: * Young children (defined as those attending pre-school groups, nursery or those aged less than 2 years) * Individual(s) who is (are) immunocompromised. * Scheduled elective surgery or other procedures requiring general anaesthesia during the study period. * Participants who have participated in another research study involving an investigational product that might affect risk of paratyphoid infection or compromise the integrity of the study within the 30 days prior to enrolment (e.g. significant volumes of blood already taken in previous study) . * Detection of any abnormal results from screening investigations (at the clinical discretion of the study investigators). * Inability to comply with any of the study requirements (at the discretion of the study investigators and the participants General Practitioner). * Any other social, psychological or health issues which, in the opinion of the study investigator, may * Put the participants or their contacts at risk because of participation in the study, * Adversely affect the interpretation of the primary endpoint data, * Impair the participant's ability to participate in the study. * Having previously received any live oral typhoid vaccine (those who have received Vi polysaccharide vaccine will not be excluded). * Having been resident in an enteric fever endemic country 6 months or more. * Have previously been diagnosed with laboratory-confirmed typhoid or paratyphoid infection or been given a diagnosis compatible with enteric fever. * Have participated in previous typhoid challenge studies (with ingestion of challenge agent). * Currently working for the Oxford Vaccine Group.

Outcomes

Primary Outcomes

Clinical or microbiologically proven paratyphoid infection.

Clinical or microbiologically proven paratyphoid infection following oral challenge with Salmonella Paratyphi A, strain NVGH308, delivered with sodium bicarbonate solution.

Time frame: Up to 14 days after challenge dose administered

Secondary Outcomes

Human physiological response

Description of the clinical course after challenge using, for example, participant symptom profiles, temperature measurements and other recorded clinical and laboratory observations. The outcomes will be measured in terms of number of participants and/or proportion of participants developing a certain clinical observation. For certain observations mean time from dosing to the development of that observation (e.g. development of a temperature \>38C).

Time frame: Clinical signs and solicited symptoms measured in the 21 day period after challenge; laboratory and unsolicited symptoms followed up over the course of one year

Evaluation of the sensitivity of paratyphoid diagnostic criteria

Determination of challenge dose/kg (dose/surface area) actually ingested by those developing and those not developing paratyphoid infection at each dose level. Analysis of the attack rate using alternative criteria including, for example, passive field surveillance definitions, alternative temperature thresholds and adjunctive microbiological and laboratory diagnostic assays.